AAV9-mediated VEGF-B gene transfer improves systolic function in progressive left ventricular hypertrophy

Molecular Therapy

Volumn 20, Issue 12, 2012, Pages 2212-2221

  Huusko, Jenni ^a   Lottonen, Line ^a   Merentie, Mari ^a   Gurzeler, Erika ^a   Anisimov, Andrey ^b   Miyanohara, Atsushi ^c   Alitalo, Kari ^b   Tavi, Pasi ^a   Ylä Herttuala, Seppo ^a  

^a UNIVERSITY OF EASTERN FINLAND   (Finland)

^b UNIVERSITY OF HELSINKI   (Finland)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN RECEPTOR 3;

ADENO ASSOCIATED VIRUS; ADENO ASSOCIATED VIRUS SEROTYPE 9; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; AORTA CONSTRICTION; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE; GENE EXPRESSION REGULATION; GLYCOGEN ANALYSIS; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; INHIBITION KINETICS; MALE; MOUSE; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; SYSTOLIC BLOOD PRESSURE; UPREGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR B GENE; VIRAL GENE DELIVERY SYSTEM;

ADENO-ASSOCIATED VIRUS; MUS;

EID: 84870589839     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.145     Document Type: Article

References (45)

1. Katholi, RE and Couri, DM (2011). Left ventricular hypertrophy: major risk factor in patients with hypertension: update and practical clinical applications. Int J Hypertens 2011: 495349.
2. Hunter, JJ and Chien, KR (1999). Signaling pathways for cardiac hypertrophy and failure. N Engl J Med 341: 1276-1283.
3. Rimbaud, S, Sanchez, H, Garnier, A, Fortin, D, Bigard, X, Veksler, V et al. (2009). Stimulus specific changes of energy metabolism in hypertrophied heart. J Mol Cell Cardiol 46: 952-959.
4. Lorell, BH and Carabello, BA (2000). Left ventricular hypertrophy: pathogenesis, detection, and prognosis. Circulation 102: 470-479.
5. Levy, D, Garrison, RJ, Savage, DD, Kannel, WB and Castelli, WP (1990). Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322: 1561-1566.
6. Frey, N and Olson, EN (2003). Cardiac hypertrophy: the good, the bad, and the ugly. Annu Rev Physiol 65: 45-79.
7. Walsh, K and Shiojima, I (2007). Cardiac growth and angiogenesis coordinated by intertissue interactions. J Clin Invest 117: 3176-3179.
8. Izumiya, Y, Shiojima, I, Sato, K, Sawyer, DB, Colucci, WS and Walsh, K (2006). Vascular endothelial growth factor blockade promotes the transition from compensatory cardiac hypertrophy to failure in response to pressure overload. Hypertension 47: 887-893.
9. Shiojima, I, Sato, K, Izumiya, Y, Schiekofer, S, Ito, M, Liao, R et al. (2005). Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. J Clin Invest 115: 2108-2118.
10. Ylä-Herttuala, S, Rissanen, TT, Vajanto, I and Hartikainen, J (2007). Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. J Am Coll Cardiol 49: 1015-1026.
11. Ferrara, N (2004). Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 25: 581-611.
12. Rissanen, TT and Ylä-Herttuala, S (2007). Current status of cardiovascular gene therapy. Mol Ther 15: 1233-1247.
13. Lähteenvuo, JE, Lähteenvuo, MT, Kivelä, A, Rosenlew, C, Falkevall, A, Klar, J et al. (2009). Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms. Circulation 119: 845-856.
14. Bry, M, Kivelä, R, Holopainen, T, Anisimov, A, Tammela, T, Soronen, J et al. (2010). Vascular endothelial growth factor-B acts as a coronary growth factor in transgenic rats without inducing angiogenesis, vascular leak, or inflammation. Circulation 122: 1725-1733.
15. Hagberg, CE, Falkevall, A, Wang, X, Larsson, E, Huusko, J, Nilsson, I et al. (2010). Vascular endothelial growth factor B controls endothelial fatty acid uptake. Nature 464: 917-921.
16. Serpi, R, Tolonen, AM, Huusko, J, Rysä, J, Tenhunen, O, Ylä-Herttuala, S et al. (2011). Vascular endothelial growth factor-B gene transfer prevents angiotensin II-induced diastolic dysfunction via proliferation and capillary dilatation in rats. Cardiovasc Res 89: 204-213.
17. Li, X, Tjwa, M, Van Hove, I, Enholm, B, Neven, E, Paavonen, K et al. (2008). Reevaluation of the role of VEGF-B suggests a restricted role in the revascularization of the ischemic myocardium. Arterioscler Thromb Vasc Biol 28: 1614-1620.
18. Li, Y, Zhang, F, Nagai, N, Tang, Z, Zhang, S, Scotney, P et al. (2008). VEGF-B inhibits apoptosis via VEGFR-1-mediated suppression of the expression of BH3-only protein genes in mice and rats. J Clin Invest 118: 913-923.
19. Achen, MG, Jeltsch, M, Kukk, E, Mäkinen, T, Vitali, A, Wilks, AF et al. (1998). Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4). Proc Natl Acad Sci USA 95: 548-553.
20. Joukov, V, Pajusola, K, Kaipainen, A, Chilov, D, Lahtinen, I, Kukk, E et al. (1996). A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases. EMBO J 15: 1751.
21. Rissanen, TT, Markkanen, JE, Gruchala, M, Heikura, T, Puranen, A, Kettunen, MI et al. (2003). VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 92: 1098-1106.
22. Tirziu, D, Chorianopoulos, E, Moodie, KL, Palac, RT, Zhuang, ZW, Tjwa, M et al. (2007). Myocardial hypertrophy in the absence of external stimuli is induced by angiogenesis in mice. J Clin Invest 117: 3188-3197.
23. Accornero, F, van Berlo, JH, Benard, MJ, Lorenz, JN, Carmeliet, P and Molkentin, JD (2011). Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. Circ Res 109: 272-280.
24. Nash, AD, Baca, M, Wright, C and Scotney, PD (2006). The biology of vascular endothelial growth factor-B (VEGF-B). Pulm Pharmacol Ther 19: 61-69.
25. Hilfiker-Kleiner, D, Hilfiker, A, Kaminski, K, Schaefer, A, Park, JK, Michel, K et al. (2005). Lack of JunD promotes pressure overload-induced apoptosis, hypertrophic growth, and angiogenesis in the heart. Circulation 112: 1470-1477.
26. Kaza, E, Ablasser, K, Poutias, D, Griffiths, ER, Saad, FA, Hofstaetter, JG et al. (2011). Up-regulation of soluble vascular endothelial growth factor receptor-1 prevents angiogenesis in hypertrophied myocardium. Cardiovasc Res 89: 410-418.
27. Abraham, D, Hofbauer, R, Schäfer, R, Blumer, R, Paulus, P, Miksovsky, A et al. (2000). Selective downregulation of VEGF-A(165), VEGF-R(1), and decreased capillary density in patients with dilative but not ischemic cardiomyopathy. Circ Res 87: 644-647.
28. Park, JH, Yoon, JY, Ko, SM, Jin, SA, Kim, JH, Cho, CH et al. (2011). Endothelial progenitor cell transplantation decreases lymphangiogenesis and adverse myocardial remodeling in a mouse model of acute myocardial infarction. Exp Mol Med 43: 479-485.
29. Kholová, I, Dragneva, G, Cermáková, P, Laidinen, S, Kaskenpää, N, Hazes, T et al. (2011). Lymphatic vasculature is increased in heart valves, ischaemic and inflamed hearts and in cholesterol-rich and calcified atherosclerotic lesions. Eur J Clin Invest 41: 487-497.
30. Pätilä, T, Ikonen, T, Rutanen, J, Ahonen, A, Lommi, J, Lappalainen, K et al. (2006). Vascular endothelial growth factor C-induced collateral formation in a model of myocardial ischemia. J Heart Lung Transplant 25: 206-213.
31. Boström, P, Mann, N, Wu, J, Quintero, PA, Plovie, ER, Panáková, D et al. (2010). C/ EBPß controls exercise-induced cardiac growth and protects against pathological cardiac remodeling. Cell 143: 1072-1083.
32. Hsieh, PC, Segers, VF, Davis, ME, MacGillivray, C, Gannon, J, Molkentin, JD et al. (2007). Evidence from a genetic fate-mapping study that stem cells refresh adult mammalian cardiomyocytes after injury. Nat Med 13: 970-974.
33. Bersell, K, Arab, S, Haring, B and Kühn, B (2009). Neuregulin1/ErbB4 signaling induces cardiomyocyte proliferation and repair of heart injury. Cell 138: 257-270.
34. Kho, C, Lee, A, Jeong, D, Oh, JG, Chaanine, AH, Kizana, E et al. (2011). SUMO1- dependent modulation of SERCA2a in heart failure. Nature 477: 601-605.
35. Zentilin, L, Puligadda, U, Lionetti, V, Zacchigna, S, Collesi, C, Pattarini, L et al. (2010). Cardiomyocyte VEGFR-1 activation by VEGF-B induces compensatory hypertrophy and preserves cardiac function after myocardial infarction. FASEB J 24: 1467-1478.
36. Huusko, J, Merentie, M, Dijkstra, MH, Ryhänen, MM, Karvinen, H, Rissanen, TT et al. (2010). The effects of VEGF-R1 and VEGF-R2 ligands on angiogenic responses and left ventricular function in mice. Cardiovasc Res 86: 122-130.
37. Pepe, M, Mamdani, M, Zentilin, L, Csiszar, A, Qanud, K, Zacchigna, S et al. (2010). Intramyocardial VEGF-B167 gene delivery delays the progression towards congestive failure in dogs with pacing-induced dilated cardiomyopathy. Circ Res 106: 1893- 1903.
38. Ventura-Clapier, R, Garnier, A and Veksler, V (2004). Energy metabolism in heart failure. J Physiol (Lond) 555(Pt 1): 1-13.
39. Garnier, A, Fortin, D, Deloménie, C, Momken, I, Veksler, V and Ventura-Clapier, R (2003). Depressed mitochondrial transcription factors and oxidative capacity in rat failing cardiac and skeletal muscles. J Physiol (Lond) 551(Pt 2): 491-501.
40. Dai, DF, Hsieh, EJ, Liu, Y, Chen, T, Beyer, RP, Chin, MT et al. (2012). Mitochondrial proteome remodelling in pressure overload-induced heart failure: the role of mitochondrial oxidative stress. Cardiovasc Res 93: 79-88.
41. Tavi, P, Laine, M, Weckström, M and Ruskoaho, H (2001). Cardiac mechanotransduction: from sensing to disease and treatment. Trends Pharmacol Sci 22: 254-260.
42. Ronkainen, JJ, Vuolteenaho, O and Tavi, P (2007). Calcium-calmodulin kinase II is the common factor in calcium-dependent cardiac expression and secretion of A- and B-type natriuretic peptides. Endocrinology 148: 2815-2820.
43. Rockman, HA, Ross, RS, Harris, AN, Knowlton, KU, Steinhelper, ME, Field, LJ et al. (1991). Segregation of atrial-specific and inducible expression of an atrial natriuretic factor transgene in an in vivo murine model of cardiac hypertrophy. Proc Natl Acad Sci USA 88: 8277-8281.
44. Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr et al. (2002). Production and purification of serotype 1, 2, and 5 recombinant adeno-associated viral vectors. Methods 28: 158-167.
45. Gao, G, Qu, G, Burnham, MS, Huang, J, Chirmule, N, Joshi, B et al. (2000). Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther 11: 2079-2091.